Exagen Inc. (NASDAQ:XGN) Short Interest Down 42.0% in April

Exagen Inc. (NASDAQ:XGN) saw a significant decline in short interest in April. As of April 15th, there was short interest totalling 11,900 shares, a decline of 42.0% from the March 31st total of 20,500 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average daily volume of 38,200 shares, the days-to-cover ratio is currently 0.3 days.

Exagen Stock Up 0.7 %

NASDAQ XGN opened at $1.42 on Friday. The company has a market capitalization of $24.48 million, a price-to-earnings ratio of -1.06 and a beta of 1.19. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.85. Exagen has a 1-year low of $1.30 and a 1-year high of $3.92. The stock’s 50 day moving average is $1.68 and its two-hundred day moving average is $1.77.

Exagen (NASDAQ:XGN) last announced its earnings results on Monday, March 18th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.02). The business had revenue of $13.77 million during the quarter, compared to analyst estimates of $11.43 million. Exagen had a negative return on equity of 80.28% and a negative net margin of 45.08%. During the same period in the previous year, the firm earned ($0.58) earnings per share. Equities analysts forecast that Exagen will post -1.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of XGN. Stonepine Capital Management LLC boosted its holdings in shares of Exagen by 14.7% in the 3rd quarter. Stonepine Capital Management LLC now owns 1,203,491 shares of the company’s stock worth $2,912,000 after acquiring an additional 154,139 shares in the last quarter. Perkins Capital Management Inc. boosted its holdings in shares of Exagen by 92.8% in the 4th quarter. Perkins Capital Management Inc. now owns 508,905 shares of the company’s stock worth $1,013,000 after acquiring an additional 245,000 shares in the last quarter. Finally, RTW Investments LP raised its position in Exagen by 0.8% in the 4th quarter. RTW Investments LP now owns 1,504,602 shares of the company’s stock worth $2,994,000 after purchasing an additional 12,170 shares during the last quarter. 75.25% of the stock is owned by institutional investors and hedge funds.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).